| October 2010 · Vol. 22, No. 10 Q&A WITH ANDREW M. KAUNITZ, MD
An ObGyn’s guide
to aromatase inhibitors
as adjuvant therapy for breast CA
You may not prescribe anastrozole, letrozole, or exemestane, but there’s a strong possibility that some of your patients are taking one of these medications. Here’s what you need to know to encourage compliance and ease their ill effects.
|
Fast Track
All third-generation aromatase inhibitors have similar effects on skeletal health and produce similar side effects in postmenopausal women
All major phase-3 trials of adjuvant use of AIs in women who have early breast cancer found an increased risk of fracture
Early discontinuation or noncompliance with aromatase inhibitor therapy is associated with higher mortality
|
|
Andrew
M.
Kaunitz,
MDDr. Kaunitz is Professor and associate Chairman of the Department of Obstetrics and Gynecology at the University of Florida College of Medicine– Jacksonville in Jacksonville, Fla. He serves on the OBG Management Board of Editors. Janelle
YatesSenior Editor, OBG Management
Dr. Kaunitz reports no financial relationships relevant to this article.
Think breast cancer survivors are unlikely to show up in your practice? You should think again.
|
